The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.
(Bloomberg) -- The $475,000 price tag on Novartis AG’s latest breakthrough cancer therapy came under fire from one of the biggest managers of drug costs in the U.S., underscoring the challenges the Swiss drugmaker will face in promoting the potential blockbuster.
The cost of the leukemia treatment, called Kymriah, is “dramatically higher” than other such complex treatments, and the health-care system isn’t ready to pay for it, Steve Miller, chief medical officer at Express Scripts Holding Co., said Thursday in a blog post on his company’s website. Gene therapies like Novartis’s are targeted at a small number of patients and typically used just once, meaning that drug companies have limited chances to recoup their investment
‘Therein lies the challenge,” Miller wrote. “We need a new payment model.”
Kymriah is the first drug approved from a new class of treatments called CAR-Ts that have been heralded as a promising approach to treating and potentially curing cancers as well as genetic conditions such as blindness. Paying for CAR-Ts and similar therapies, some of which cost as much as $1.4 million, will require new collaborative approaches among payers, drugmakers and policymakers, the executive wrote.
Novartis has previously said it will attempt to address the pricing hurdle with a new type of agreement: for patients whose care is covered by U.S. government programs, the company will only get paid if patients show signs that the treatment is working within a month of getting it.
Shares of the Swiss company fell 0.2 percent to 82.80 Swiss francs as of 10:12 a.m. in Zurich.
Express Scripts, a pharmacy benefit manager or intermediary in the U.S. health-care system, negotiates on prices with drugmakers to lower costs for its clients.
--With assistance from James Paton
To contact the reporter on this story: John Lauerman in London at email@example.com.
To contact the editor responsible for this story: Chitra Somayaji at firstname.lastname@example.org.
©2017 Bloomberg L.P.